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Abstract
Background: Acute lymphoblastic leukemia (ALL) is a common form of cancer in children. Currently,
bone marrow biopsy is used for diagnosis. Noninvasive biomarkers for the early diagnosis of pediatric ALL
are urgently needed. The aim of this study was to discover potential protein biomarkers for pediatric ALL.
Methods: Ninety-four pediatric ALL patients and 84 controls were randomly divided into a "training" set
(45 ALL patients, 34 healthy controls) and a test set (49 ALL patients, 30 healthy controls and 30 pediatric
acute myeloid leukemia (AML) patients). Serum proteomic profiles were measured using surface-enhanced
laser desorption/ionization-time-of-flight mass spectroscopy (SELDI-TOF-MS). A classification model was
established by Biomarker Pattern Software (BPS). Candidate protein biomarkers were purified by HPLC,
identified by LC-MS/MS and validated using ProteinChip immunoassays.
Results: A total of 7 protein peaks (9290 m/z, 7769 m/z, 15110 m/z, 7564 m/z, 4469 m/z, 8937 m/z, 8137
m/z) were found with differential expression levels in the sera of pediatric ALL patients and controls using
SELDI-TOF-MS and then analyzed by BPS to construct a classification model in the "training" set. The
sensitivity and specificity of the model were found to be 91.8%, and 90.0%, respectively, in the test set.
Two candidate protein peaks (7769 and 9290 m/z) were found to be down-regulated in ALL patients,
where these were identified as platelet factor 4 (PF4) and pro-platelet basic protein precursor (PBP). Two
other candidate protein peaks (8137 and 8937 m/z) were found up-regulated in the sera of ALL patients,
and these were identified as fragments of the complement component 3a (C3a).
Conclusion: Platelet factor (PF4), connective tissue activating peptide III (CTAP-III) and two fragments of
C3a may be potential protein biomarkers of pediatric ALL and used to distinguish pediatric ALL patients
from healthy controls and pediatric AML patients. Further studies with additional populations or using pre-
diagnostic sera are needed to confirm the importance of these findings as diagnostic markers of pediatric
ALL.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
pediatric cancer, accounting for 30% of all pediatric
malignancies [1]. ALL is diagnosed in 3000 to 4000 per-
sons in the United States each year, where two-thirds of
these are children [2,3]. ALL can develop from any lym-
phoid cell blocked at a particular stage of development,
including primitive cells with multilineage potential
[4,5]. The diagnosis of ALL presently depends on immu-
nophenotyping. Although more than 339 different clus-
ter-of-differentiation (CD) molecules expressed on
human leukocytes are defined [6], only a few of these
molecules are truly lineage-specific. Melhem reported that
oncoprotein 18 (Op18) phosphorylation was signifi-
cantly correlated with the white blood cell count and the
percentage of cells in S phase [7]. However, Brattsand and
Chen reported that over-phosphorylation of Op18 was
also found in breast cancer and lung adenocarcinomas
[8,9]. Noninvasive and specific biomarkers for early diag-
noses of pediatric ALL remain an urgent need.
Proteome analysis provides valuable information about
the total proteome's dynamic and rapid changes occurring
during illness. Recent advances in proteomics have
offered opportunities for finding biomarkers in biological
fluids, especially in sera. Surface-assisted laser desorption/
ionization time-of-flight mass spectrometry (SELDI-TOF-
MS), which generates protein fingerprints, has been
proven as a powerful tool for potential biomarker discov-
ery [10,11]. Recently, SELDI-TOF-MS analysis has been
successfully used to identify specific biomarkers for vari-
ous cancers, such as prostate cancer, bladder cancer, ovar-
ian cancer, lung cancer, colon cancer, breast cancer and
pancreatic cancer [12-21]. Albitar explored the potential
of proteomic analysis of peripheral blood plasma, using
SELDI-TOF-MS, to predict the recurrence of ALL in adult
patients and build a proteomic-based model predicting
clinical behaviors in adult ALL [22]. Hegedus used SELDI-
TOF-MS to analyze proteomes of pediatric leukemia cell
lines, including ALL, mixed lineage leukemia (MLL) and
acute myeloid leukemia (AML) cell lines, and pediatric
leukemia bone marrow samples of different subtypes. Dif-
ferences in protein expression were reported among ALL,
MLL and AML cell lines and bone marrow. A protein of
8.3 kDa was found to be expressed at high levels in the
ALL cell line as well as in bone marrow and was identified
as a C-terminal truncated form of ubiquitin after purifica-
tion and trypsin digestion. These results may guide further
research toward understanding the development of leuke-
mias [23].
In this study, we first used SELDI-TOF-MS technology to
screen potential protein patterns specific to ALL, then
purified the candidate protein biomarker peaks by HPLC
and identified them by LC-MS/MS.
Materials and methods
Patients, controls and serum samples
The pediatric ALL patients were randomly selected from
patients who had been confirmed by myelocytic cytologi-
cal diagnosis in China-Japan Friendship Hospital during a
given period of time (2004.7–2004.8). At the same time,
the healthy controls were selected from children who took
health examinations required for school or kindergarten
entrance and had not been diagnosed with any other dis-
ease. Furthermore, the pediatric AML patients were also
taken as controls from this hospital. Serum samples (n =
178) were collected from 94 ALL patients, ranging in ages
from 2–14, 54 healthy children, and 30 pediatric acute
myeloid leukemia (AML) patients. The three groups were
similar in age and gender distribution (Table 1). All the
serum samples were collected from the selected patients
and controls in 2004. Informed consent was obtained
from each participant. The collected sera were immedi-
ately centrifuged at 1500 × g, 4°C for 10 min after acqui-
sition, then distributed into 20 μL/tube, and stored at -
80°C for further analysis. All the SELDI-TOF-MS experi-
ments were finished within three months.
SELDI-TOF-MS analysis of serum protein profiles
Protein profiling of serum samples was determined by
SELDI-TOF-MS using the eight-spot format WCX2 (weak
cation exchange) Proteinchip arrays (Ciphergen Biosys-
tems, Fremont, CA, USA). Frozen serum samples were
thawed on ice and spun at 10,000 rpm for 5 min at 4°C.
Each serum sample (10 μL) was denatured by the addition
Table 1: Age and sexual distribution of all study subjects in the SELDI-TOF-MS experiments
Age (years) Gender total Training set Test set
0–3 4–6 7–10 11–14 M (%) F (%)
ALL patients (M*/F**) 8/5 25/12 25/12 4/3 66.0% 34.0% 94 45 49
Healthy controls (M/F) 5/3 15/7 13/6 3/2 66.7% 33.3% 54 34 20
AML patients (M/F) 3/2 8/5 7/3 1/1 63.3% 36.7% 30 30
Total 16/10 48/24 45/21 8/6 65.7% 34.3% 178 79 99
M*: Male, F**: Female.Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
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of 20 μL of U9 buffer (9 M urea, 2% CHAPS, 50 mM Tris-
HCl, 1% DTT, pH 9.0) and vortexed at 4°C for 30 min.
Each sample was then diluted in 108 μL of low-stringency
buffer (0.1 M sodium acetate, pH 4.0). At this point, 100
μL of each diluted serum sample were ready to hybridize
with WCX2 Proteinchip arrays. The samples were held by
a bioprocessor (Ciphergen Biosystems) and preactivated
twice with 150 μL low stringency buffer at room tempera-
ture for 5 min. The diluted serum sample was allowed to
react with the surface of the WCX2 chip for 60 min at
room temperature. Each spot was then washed three times
with appropriate buffers of various pHs and ionic
strengths to eliminate non-adsorbed proteins. After dry-
ing the array surface in the air, 1 μL of saturated sinapinic
acid (SA) matrix in 50% ACN and 0.5% TFA was applied
and allowed to dry. MS analysis was performed on a PBS-
II ProteinChip reader (Ciphergen Biosystems). Mass peak
detection was analyzed using ProteinChip Biomarker
Software version 3.1 (Ciphergen Biosystems). The mass
spectra of the proteins were generated using an average of
90 laser shots at a laser intensity of 150–160 arbitrary
units, and detector sensitivity was set at 8. For data acqui-
sition of low-molecular weight proteins, the optimized
detection mass range was set from 5 to 20 kDa for all
study sample profiles. The m/z of each peak to be quanti-
fied (S/N ratio>5) was determined according to externally
calibrated standards (Ciphergen Biosystems). The m/z
sample peaks with more than 2000 m/z were normalized
with Biomarker Wizard to compile all spectra and auto-
matically detect quantified mass peaks.
Bioinformatics and biostatistics
Serum samples were split into two groups, the training set
or test set. Forty-five samples from ALL patients and 34
healthy controls were randomly selected for training sam-
ple set. To evaluate the accuracy and validity of the classi-
fication tree, 49 samples of ALL patients and 50 controls
(20 healthy children and 30 patients with pediatric AML)
were selected for the test set (Table 1).
The profiling spectra of serum samples from the training
set were normalized using total ion current normalization
by Ciphergen's ProteinChip Software (version 3.1). Peak
labeling was performed by the Biomarker Wizard feature
of the software. A two-sample t-test was used to compare
mean normalized intensities between the case and control
groups. The p value was set at 0.05 to be statistically signif-
icant. The intensities of selected peaks were then trans-
ferred to Biomarker Pattern Software (BPS) to construct
the classification tree of ALL. Briefly, the intensities of the
selected peaks were submitted to BPS as a 'Root note'.
Based on peak intensity, a threshold was determined by
BPS to classify the root node into two child nodes. If the
peak intensity of a blind sample was lower than or equal
to the threshold, this peak would be labeled as "left-side
child node." Peak intensities higher than the threshold
would be marked as "right-side child node." After rounds
of decision making, the training set was found to be dis-
criminatory with the least error.
All of the protein peak intensities of samples in the test set
were evaluated by BPS using the classification model. The
ALL and control samples were then discriminated based
on their proteomic profile characteristics. The sensitivity
was defined as the probability of predicting ALL cases, and
the specificity was defined as the probability of predicting
control samples. A positive predictive value reflected the
probability of ALL if a test result was positive.
Serum fractionation
Serum samples from both healthy controls and ALL
patients were selected for the purification of the four can-
didate protein biomarkers. The serum sample was mixed
with U9 buffer (1:2, v/v) and incubated for 30 min at
room temperature. The sample was then diluted in 5 mL
of WCX binding buffer (50 mM NaAc, pH 4.0) and loaded
to the CM Ceramic Hyper D WCX SPE column (6 × 10
mm, Pall Life science, USA). After washing with 2 mL of
WCX binding buffer, the column was eluted with 5 mL of
eluting buffer (2 M NaCl, 50 mM NaAc, pH 4.0) at a flow
rate of 0.5 mL/min. The eluted fraction was further puri-
fied using HPLC.
Purification of candidate protein markers using HPLC
HPLC separation was performed using SCL-10AVP (Shi-
madzu, Japan) with a Sunchrom C18 column (250 × 4.6
mm, 5 μm particle size, 300 Å) (The Great Eur-Asia Sci-
Tech Development Co. Ltd, Beijing, China) and a C18
guard column (10 × 3 mm, Shimadzu, Japan). The mobile
phase consisted of solvent A (5% ACN, 0.1% TFA) and
solvent B (90% ACN, 0.1%TFA). The HPLC separation
was achieved with a linear solvent gradient: 100% A (0
min)-15% B (15 min)-65% B (65 min)-100% B (100
min) at a flow rate of 0.5 mL/min. The eluate emissions
were detected at multiple wavelengths of 214, 254, and
280 nm. Each peak fraction was collected and concen-
trated using SpeedVac, and then analyzed using an
AXIMA-CFRTM plus MALDI-TOF mass spectrometer (Shi-
madzu/Kratos, Manchester, UK) in linear mode to trace
the candidate protein biomarkers with α-cyano-4-hydro-
rycinnamic acid (CHCA) as the matrix.
Identification of candidate protein biomarkers by LC-MS/
MS
In-solution digestion of each concentrated fraction, which
contains one candidate protein biomarker, was per-
formed with a standard protocol. Briefly, each fraction
was dissolved in 25 mM NH4HCO3, reduced with 10 mMProteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
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DTT for 1 hour, and alkylated by 40 mM iodacetamide in
the dark for 45 minutes at room temperature. Then, 40
mM DTT was added to quench the iodacetamide for 30
min at room temperature. Protease K (0.1 μg, Promega
Corporation, USA) was then added into the sample solu-
tion and incubated for 45 min at 37°C. The digestion was
stopped by adding formic acid to a final concentration of
0.1%. The digested sample was loaded onto a homemade
C18 column (100 mm ×100 μm) packed with Sunchrom
packing material (SP-120-3-ODS-A, 3 μm) and followed
by nano-LC-ESI-MS/MS analysis. The LTQ mass spectrom-
eter was operated in the data-dependent mode in which
first the initial MS scan recorded the mass to charge (m/z)
ratios of ions over the mass range from 400–2000 Da. The
five most abundant ions were automatically selected for
subsequent collision-activated dissociation. All MS/MS
data were searched against a human protein database
downloaded from the NCBI database using the SEQUEST
program (Thermo, USA).
Confirmation of candidate protein biomarkers using 
ProteinChip immunoassays
To confirm the identity of the candidate protein biomark-
ers, specific antibodies (anti-PF4 rabbit antibody,
ab49735; anti-NAP-2 mouse antibody, ab58142, anti-
C3a mouse antibody, ab11872, all from ABcam) were
applied to each spot of pre-activated PS20 ProteinChip
arrays (Ciphergen Biosystems) and incubated overnight at
4°C in a humidity chamber. After blocking with BSA and
rinsing, antibody-coated spots were incubated with 1.5 μL
of serum samples and 3 μL of binding buffer (0.1 M
Na3PO4, 0.5 M urea, 0.5% CHAPS, pH 7.2) for 90 min
[24]. Spots were then washed with PBST (0.5% Triton X-
100), PBS and deionized water twice before drying.
SELDI-TOF-MS analysis was performed on a PBS-II Pro-
teinChip reader with CHCA as the matrix.
Results
Serum protein profiles and data processing
All the serum samples were collected from the selected
patients and controls in 2004, then distributed into 20 mL
per tube, and stored at -80°C until use. The SELDI-TOF-
MS experiments were finished within three months after
the collection of all serum samples. No significant change
of the protein markers was found during storage after
SELDI-TOF-MS and MALDI-TOF-MS analysis.
Serum samples from the training set were evaluated by
comparing the results obtained by SELDI-TOF-MS with
those from the WCX2 chip. All MS data had baseline sub-
tracted and were normalized using total ion current. Peak
clusters were then generated by Biomarker Wizard soft-
ware. Twenty-six peaks had statistically significant differ-
ences between pediatric patients and healthy children (p
value < 0.05). In the ALL group, five protein peaks were
found to be up-regulated and twenty-one peaks were
found to be down-regulated (Table 2). Figure 1 shows the
protein profiling patterns of sera from ALL patients and
control samples. The results indicated that two protein
peaks (8137 m/z, p value 6.07E-05 and 8937 m/z, p value
5.13E-05) were up-regulated in sera from ALL patients,
while two other peaks (7769 m/z, p value 1.54E-07 and
9290 m/z, p value 7.59E-08) were down-regulated, com-
pared with those from the healthy controls.
Protein peak detection and validation
To develop biomarker patterns for the diagnosis of ALL,
the intensities of the protein peaks in the training set were
submitted to BPS. A total of seven peaks (9290 m/z, 7769
m/z, 15110 m/z, 7564 m/z, 4469 m/z, 8937 m/z, 8137
m/z) with the highest discriminatory power were auto-
matically selected to construct a classification tree. Figure
2 shows the tree structure and sample distribution. The
classification tree using the combination of the five peaks
identified 45 ALL and 34 healthy subjects with a calcu-
lated sensitivity of 96% and a specificity of 98%.
To validate the accuracy and validity of the classification
model derived from the training set, we applied the
derived classification tree to a test dataset consisting of 49
ALL and 50 control samples. The classification tree dis-
criminated the ALL samples from the controls with a sen-
sitivity of 91.8% and a specificity of 90%. The positive
predictive value was found to be 90%.
Purification and identification of candidate protein 
biomarkers
Serum samples from ALL patients were used for the puri-
fication of the two up-regulated candidate protein
biomarkers (8137 and 8937 m/z), and serum samples
from healthy controls were used for the purification of the
two down-regulated proteins (7769, 9290 m/z) in the sera
from ALL patients using WCX SPE and C18 HPLC. Figure
3 shows the results of MALDI-TOF-MS analyses of the four
purified candidate protein biomarkers.
After digestion with protease K, the peptide mixture was
analyzed by nano-LC-MS/MS. Figure 4 shows the results
of the LC-MS/MS chromatogram (A) and MS/MS spectra
of two identified peptides (B, C) from the protein (9290
m/z). Table 3 shows the results of the identification of the
four candidate protein biomarkers: CTAP-III (fragment of
pro-platelet basic protein precursor, PBP, 9290 m/z), PF4
(platelet factor 4, 7769 m/z), and two fragments of C3a
(one of human complements, 8137 and 8937 m/z). A
combination of high sequence coverage and accurate MW
measurement by MALDI-TOF-MS provided a complete
sequence of the four candidate protein markers.Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
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Representative mapping of SELDI-TOF-MS analysis of sera from healthy controls and pediatric ALL patients Figure 1
Representative mapping of SELDI-TOF-MS analysis of sera from healthy controls and pediatric ALL patients. 
Differentially expressed proteins with potential diagnostic significance are indicated by arrows. The top group denotes serum 
from a healthy volunteer, in which 7769 m/z and 9290 m/z were up-regulated. The bottom group denotes sera from patients 
with ALL, in which 8137 m/z and 8937 m/z were over-expressed.Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
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Validation of four candidate protein biomarkers
To confirm the identity of the four proteins as PF4,
CTAPIII, and two fragments of C3a, we performed immu-
noassays with specific antibodies directed against the four
proteins immobilized on a ProteinChip (Ciphergen Bio-
systems). The results showed that the CTAP-III and PF4
were captured and detected in the serum of healthy, but
not ALL patients, controls, and the fragments of C3a in the
serum of ALL patients, but not healthy controls (Figure 5).
Discussion
In this study, we obtained serum protein mass spectra
from pediatric ALL patients and controls using SELDI-
TOF-MS. During the pilot study, we tried SCX2, WCX,
IMAC-Cu, IMAC-Ni and H4 protein chips for the sera
samples. Eventually, we found that more protein peaks
were detected using the WCX protein chip to assay serum
samples (data not shown in this paper.) Based on the
serum proteomic profiles, we constructed a classification
model to discriminate the ALL patients from the healthy
controls. We used a two-step approach for proteomic
biomarker screening. First, we employed a "training set"
to identify differentially expressed proteins and used the
distinguishing proteomic peaks from BPS for the con-
struction of a classification tree. The classification model
discriminated patients with ALL from healthy controls
and pediatric AML with a sensitivity of 91.8% and a spe-
cificity of 90.0%.
Two down-regulated candidate protein biomarkers were
identified as PF4 (platelet factor 4, 7769 m/z) and CTAP-
III (fragment of pro-platelet basic protein precursor, PBP,
9290 m/z). Additionally, two up-regulated candidate pro-
tein biomarkers (8137 and 8937 m/z) were identified as
two fragments of C3a.
Among the proteins identified by LC-MS/MS, both PF4
and CTAP-III are platelet-derived chemokines. PF4, which
is also known as CXCL4, is present in platelet α-granules
and is released during platelet aggregation. PF4 is also
released from activated T lymphocytes and mast cells [25].
PF4 has been reported to influence many biological proc-
esses, including endothelial cell proliferation, migration,
and angiogenesis [26-28]. PF4 can down-regulate cell pro-
liferation and cytokine release, thereby inhibiting T cell
functions [29], and could support the survival of normal
hematopoietic precursors, protecting them from the toxic-
ity of chemotherapeutic agents [30]. CTAP-III is an N-ter-
minal cleavage product of PBP, which is synthesized by
megakaryocytes. CTAP-III, β-thromboglobulin and NAP-
2, which are derived from PBP through proteolysis,
belong to a group of homologous and immunologically
cross-reactive proteins derived from platelet α-granules. It
was reported that CTAP-III could support stem cell-
Table 2: The average peak intensity of proteins found in the sera 
of pediatric ALL patients.
m/z Children with ALL Healthy children p value
Mean SD Mean SD
9290.355 9.730 5.685 18.405 5.858 7.19E-08
7768.866 9.912 6.651 20.817 8.488 1.54E-07
15108.479 1.372 2.172 4.166 4.963 4.91E-07
7565.087 2.059 3.169 6.044 6.228 2.21E-06
4473.963 10.652 6.843 5.248 2.698 2.57E-05
8936.734 18.490 14.282 6.568 3.907 5.13E-05
8137.299 19.247 17.181 4.160 3.109 5.35E-05
28011.161 0.372 0.229 0.518 0.223 4.56E-04
15850.461 1.338 1.560 2.452 2.713 5.91E-04
5637.825 15.612 9.664 25.800 14.650 8.78E-04
4070.961 7.856 6.540 3.095 3.291 1.38E-03
3220.724 4.879 3.041 6.831 2.563 1.53E-03
4349.558 13.206 6.407 17.579 5.704 2.53E-03
6434.393 25.869 12.180 32.709 8.287 3.38E-03
23416.789 0.450 0.251 0.603 0.272 5.56E-03
4095.034 40.820 19.852 54.436 16.976 5.91E-03
2045.834 9.700 3.396 12.768 5.107 7.08E-03
7954.897 1.713 1.242 2.584 1.890 1.00E-02
2068.902 4.773 2.398 6.868 4.203 1.29E-02
2758.988 4.654 3.663 6.351 3.866 1.61E-02
4117.262 11.073 7.452 14.543 5.564 1.70E-02
5906.757 10.203 9.880 15.548 11.738 2.66E-02
8689.917 39.521 13.873 46.393 11.731 2.79E-02
4139.322 9.727 5.229 12.083 4.372 3.67E-02
6855.835 6.737 2.966 5.535 2.367 4.34E-02
8562.074 20.170 11.250 23.342 7.977 4.99E-02Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
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derived hematopoiesis [30]. Both PF4 and CTAP-III could
protect early cells from the toxic effects of various chemo-
therapeutic agents [30]. Vermeulen found that average
levels of PF4 and CTAP-III were down-regulated in the
serum of benzene-exposed workers in comparison with
control subjects [24].
Complement components play important roles as media-
tors of inflammation and immune responses. Comple-
ment 3, which is composed of α and β chains, is the most
abundant complement component in serum (1.2 mg/
mL). Complement 3 convertase could cleave C3 at the res-
idues Arg726- Ser 727 giving rise to C3b (Mr 176000 Da)
and C3a (Mr 9000 Da) [31]. C3a was reported to be an
inflammatory mediator of innate immune responses [32],
suggesting that C3a might represent an inflammation
biomarker. C3a was found to be up-regulated in the ascitic
fluids of ovarian cancer patients [33]. Lee found that C3a
is elevated in patients with chronic hepatitis C and HCV-
related hepatocellular carcinoma [34]. The 8.1 kDa C3a
fragment was identified for the first time.
In summary, we identified a set of protein peaks that
could discriminate pediatric ALL from healthy controls.
From the protein peaks specific for pediatric ALL disease,
we identified platelet factor (PF4), a fragment of pro-
platelet basic protein precursor (CTAP-III) and C3a as
potential proteomic biomarkers of pediatric ALL. This
panel of markers is likely to be limited to distinguishing
pediatric ALL from healthy controls and pediatric AML
patients. Further studies with additional populations or
using pre-diagnostic sera are needed to confirm the
importance of these findings as diagnostic markers of
pediatric ALL.
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Diagram of the classification tree for pediatric ALL patients and healthy controls.Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
Page 8 of 12
(page number not for citation purposes)
MALDI-TOF-MS spectra of four purified potential protein markers Figure 3
MALDI-TOF-MS spectra of four purified potential protein markers.Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
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Results of the identification of protein (9290 m/z) by LC-MS/MS Figure 4
Results of the identification of protein (9290 m/z) by LC-MS/MS. (A) Chromatogram of peptide mixture; (B, C) MS/MS 
spectra of two peptides.Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
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Table 3: Identification of the four potential protein biomarkers with identified peptides and covered sequences.
m/z Protein name Peptides identified Sequence*
9290 CTAP-III K.RNLAKGKEESLDSDLYAELR.C rnlakgkeesldsdlyaelrcmcikttsgihpkniqslevigkgthcnqveviatlkdgrkicldpdaprik
kivqkklagdesad
K.GKEESLDSDLYAEL.R
L.AKGKEESLDSDLYAELR.C
K.GKEESLDSDLYAELR.C
C.NQVEVIATLKDGRKICLDPDAPRIK.K
R.NLAKGKEESLDSDLYAELR.C
K.LAGDESAD.-
7769 PF4 T.SQVRPRHITSL.E eaeedgdlqclcvkttsqvrprhitslevikagphcptaqliatlkngrkicldlqaplykkiikklles
T.SLEVIKAGPHCPTAQ.L
C.LDLQAPLYKKIIK.K
L.EVIKAGPHCPTAQ.L
L.DLQAPLYKKIIK.K
A.GPHCPTAQLIATLK.N
L.QAPLYKKIIKKLLES.-
8137 C3a R.SVQLTEKRMDKVGKYPKELRKC.C svqltekrmdkvgkypkelrkccedgmrenpmrfscqrrtrfislgeackkvfldccnyitelrrq
ha
E.ACKKVFLDCC.N
L.GEACKKVFLDCC.N
C.CEDGMRENPMRFSCQ.R
L.GEACKKVFLDCCNYITELRRQHA.R
8937 C3a R.SVQLTEKRMDKVGKYPKELRKC.C svqltekrmdkvgkypkelrkccedgmrenpmrfscqrrtrfislgeackkvfldccnyitelrrqh
arashlgla
E.KRMDKVGKYPKELRKC.C
C.CEDGMRENPMRFSCQ.R
L.GEACKKVFLDCC.N
T.EKRMDKVGKYPKELRKC.C
L.GEACKKVFLDCCNYITELRRQ.H
*: Underlined and bold letters show the sequences corresponding to the identified peptides.Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
Page 11 of 12
(page number not for citation purposes)
Authors' contributions
YFQ and ZJZ designed the study. SLN was responsible for
laboratory studies and drafted the manuscript. ZJ carried
out the SELDI-TOF experiments. WP and LJ participated
in the purification and identification of all the biomark-
ers. FK carried out the SELDI-TOF data analysis. XZS, XP
and CTX participated in data analysis. CZY, CXL and HJJ
participated in the design of the study and helped to draft
the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by the National Key Basic Research Program of 
China (973 program) under grant 2004CB720004 and the National Natural 
Sciences Foundation of China under grants 30570466, 306705587, and 
30630033. The authors wish to thank Dr. Giovanna Tosato from the 
National Cancer Institute, NIH, USA, for her revisions of this manuscript 
and helpful suggestions.
References
1. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukae-
mia.  N Engl J Med 2004, 350:1535-1548.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997.
CA Cancer J Clin 1997, 47:5-27.
3. Cortes JE, Kantarjian HM: Acute lymphoblastic leukemia.  Cancer
1995, 76:2393-2417.
4. Pui CH, Behm FG, Crist WM: Clinical and biologic relevance of
immunologic marker studies in childhood acute lymphoblas-
tic leukemia.  Blood 1993, 82(2):343-362.
5. Pui CH: Childhood Leukemias.  New England Journal of Medicine
1995, 332:1618-1630.
6. Woolfson Adrian, Stebbing Justin, Tom Brian DM, Stoner Kerryn J,
Gilks Walter R, Kreil David P, Mulligan Stephen P, Belov Larissa,
Chrisp Jeremy S, Errington Will, Wildfire Adrian, Erber Wendy N,
Bower Mark, Gazzard Brian, Christopherson Richard I, Scott Mike A:
Conservation of unique cell-surface CD antigen mosaics in
HIV-1-infected individuals.  Blood 2005, 106:1003-1007.
Validation of four potential protein markers by SELDI immunoaffinity assay Figure 5
Validation of four potential protein markers by SELDI immunoaffinity assay. A: CTAP-III; B: PF4; C: fragments of 
C3a.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Proteome Science 2009, 7:7 http://www.proteomesci.com/content/7/1/7
Page 12 of 12
(page number not for citation purposes)
7. Melhem R, Hailat N, Kuick R, Hanash SM: Quantitative analysis of
Op 18 phosphorylation in childhood acute leukemia.  Leuke-
mia 1997, 11:1690-1695.
8. Brattsand G: Correlation of oncoprotein 18/stathmin expres-
sion in human breast cancer with established prognostic fac-
tors.  Br J Cancer 2000, 83:311-318.
9. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA,
Kuick R, Taylor JM, Kardia SL, Misek DE: Overexpression of Onco-
protein 18 Correlates with Poor Differentiation in Lung Ade-
nocarcinomas.   Mol Cell Proteomics 2003, 2(2):107-116.
10. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, Janeau
JL, Bezeaud A, Delforge D, Cubizolles M: Identification of a new
marker of hepatocellular carcinoma by serum protein profil-
ing of patients with chronic liver diseases.  Hepatology 2005,
41:40-47.
11. Ward DG, Cheng Y, N KG, Thar TT, Barget N, Wei W, Billingham
LJ, Martin A, Beaugrand M, Johnson PJ: Changes in the serum pro-
teome associated with the development of hepatocellular
carcinoma in hepatitis C-related cirrhosis.  Br J Cancer 2006,
94:287-292.
12. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong
L, Nasim S, Wright JG: Development of a Novel Proteomic
Approach for the Detection of Transitional Cell Carcinoma
of the Bladder in Urine.  Am J Pathol 2001, 158:1491-1502.
13. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH,
Semmes OJ, Schellhammer PF, Yasui Y, Feng Z: Serum Protein Fin-
gerprinting Coupled with a Pattern-matching Algorithm
Distinguishes Prostate Cancer from Benign Prostate Hyper-
plasia and Healthy Men.  Cancer Res 2002, 62(13):3609-3614.
14. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF,
Semmes OJ, Wright JG: Normal, Benign, Preneoplastic, and
Malignant Prostate Cells Have Distinct Protein Expression
Profiles Resolved by Surface Enhanced Laser Desorption/
Ionization Mass Spectrometry.  Clinical Cancer Research 2002,
8:2541.
15. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg
SM, Mills GB, Simone C, Fishman DA, Kohn EC: Use of proteomic
patterns in serum to identify ovarian cancer.  Lancet 2002,
359(9306):572-577.
16. Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt
BA, Velassco A, Trucco C, Wiegand L, Wood K: Serum Proteomic
Patterns for Detection of Prostate Cancer.  Journal of the
National Cancer Institute 2002, 94:1576-1578.
17. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF,
Feng Z, Semmes OJ, Wright JG: Boosted Decision Tree Analysis
of Surface-enhanced Laser Desorption/Ionization Mass
Spectral Serum Profiles Discriminates Prostate Cancer
from Noncancer Patients.  Clinical Chemistry 2002, 48:1835-1843.
18. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN,
Droller MJ, Stock RG: Putative protein markers in the sera of
men with prostatic neoplasms.  BJU International 2003,
92:223-225.
19. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, Reddy
ST, Farias-Eisner R: Identification of biomarkers for ovarian
cancer using strong anion-exchange ProteinChips: Potential
use in diagnosis and prognosis.  Proc Natl Acad Sci USA 2003,
100:12343-12348.
20. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H,
Kato Y, Yamori T: Rapid discovery and identification of a tis-
sue-specific tumor biomarker from 39 human cancer cell
lines using the SELDI ProteinChip platform.  Biochemical and
Biophysical Research Communications 2003, 309:18-25.
21. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS: Dis-
covery of distinct protein profiles specific for lung tumors
and pre-malignant lung lesions by SELDI mass spectrome-
try.  Lung Cancer 2003, 40:267-279.
22. Albitar M, Potts SJ, Giles FJ, O BS, Keating M, Thomas D, Clarke C,
Jilani I, Aguilar C, Estey E: Proteomic-based prediction of clinical
behavior in adult acute lymphoblastic leukemia.  Cancer 2006,
106:1587-1594.
23. Hegedus CM, Gunn L, Skibola CF, Zhang L, Shiao R, Fu S, Dalmasso
EA, Metayer C, Dahl GV, Buffler PA: Proteomic analysis of child-
hood leukemia.  Leukemia 2005, 19:1713-1718.
24. Vermeulen R, Lan Q, Zhang L, Gunn L, McCarthy D, Woodbury RL,
McGuire M, Podust VN, Li G, Chatterjee N: Decreased levels of
CXC-chemokines in serum of benzene-exposed workers
identified by array-based proteomics.  Proc Natl Acad Sci USA
2005, 102:17041-17046.
25. Boehlen FCK: Platelet chemokines and their receptors: what
is their relevance to platelet storage and transfusion prac-
tice?  Transfus Med 2001, 11(6):403-417.
26. Strieter RM, Belperio JA, Phillips RJ, Keane MP: Chemokines: Ang-
iogenesis and metastases in lung cancer.  Novartis Found Symp
2004, 256:173-184.
27. Szekanecz Z, Kim J, Koch AE: Chemokines and chemokine
receptors in rheumatoid arthritis.  Seminars in Immunology 2003,
15:15-21.
28. Szekanecz Z, Koch AE: Chemokines and angiogenesis.  Current
Opinion in Rheumatology 2001, 13:202-208.
29. Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt
E, Flad HD, Petersen F: Platelet Factor 4 Inhibits Proliferation
and Cytokine Release of Activated Human T Cells 1.  The Jour-
nal of Immunology 2002, 169:770-777.
30. Han ZC, Lu M, Li J, Defard M, Boval B, Schlegel N, Caen JP: Platelet
Factor 4 and Other CXC Chemokines Support the Survival
of Normal Hematopoietic Cells and Reduce the Chemosen-
sitivity of Cells to Cytotoxic Agents.  Blood 1997, 89:2328-2335.
31. Sahu A, Lambris JD: Structure and biology of complement pro-
tein C3, a connecting link between innate and acquired
immunity.  Immunological Reviews 2001, 180:35-48.
32. Markiewski MM, Mastellos D, Tudoran R, DeAngelis RA, Strey CW,
Franchini S, Wetsel RA, Erdei A, Lambris JD: C3a and C3b Activa-
tion Products of the Third Component of Complement (C3)
Are Critical for Normal Liver Recovery after Toxic Injury 1.
The Journal of Immunology 2004, 173:747-754.
33. Bjorge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE,
Meri S: Ascitic complement system in ovarian cancer.  Br J Can-
cer 2005, 92:895-905.
34. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen
CL, Lu FJ, Chow LP: Identification of complement C3a as a can-
didate biomarker in human chronic hepatitis C and HCV-
related hepatocellular carcinoma using a proteomics
approach.  Proteomics 2006, 6:2865-2873.